BioSpace News Archive

EV Biologics Corp, (OTC PINK:YECO), today announced that during its Q1 R&D meeting, the executive board reviewed and has approved a plan for cGMP process development and scalable biomanufacturing of exosome biopharmaceuticals. EV Biologics has designed a modular process for production of extracellular vesicles (EVs) with native therapeutic properties, beginning with optimized producer cells.

Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries, announced newest data from its ongoing nonalcoholic steatohepatitis (NASH) observational study, published in Hepatology Communications (https://doi.org/10.1002/hep4.1689).

Piccolo Medical, Inc. announces that it has received FDA clearance of its SmartPICC ™ System. The SmartPICC™ System provides caregivers the ability to navigate peripherally inserted central catheters (PICCs) to the entryway of the heart without relying on x-ray or fluoroscopy confirmation of correct catheter placement.

Corn — or maize — has changed over thousands of years from weedy plants that make ears with less than a dozen kernels to the cobs packed with hundreds of juicy kernels that we see on farms

Paragonix Technologies, the leading hypothermic cardiothoracic organ preservation provider, announced today the first-in-man clinical use of the only FDA cleared cold storage device for donor lungs, its LUNGguard™ Donor Lung Preservation System, by Duke University Hospital.

UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to trial UNI91103 (intranasal niclosamide) as a prophylactic treatment of COVID-19 in kidney patients, a vulnerable and high-risk patient population.

VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient’s First Visit in the Phase II HEART clinical study evaluating TOTUM-070, an innovative active substance for the reduction of blood LDL-cholesterol levels,

Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or attend several upcoming virtual healthcare investor events in February and March 2021.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company has acquired an exclusive license from Alexion Pharmaceuticals

Havn Life Sciences Inc., a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company in the United States.